| Lee M Glickman, MD | |
|
2 Capital Way Ste 385, Pennington, NJ 08534-2521 | |
| (609) 303-4838 | |
| (609) 303-4835 |
| Full Name | Lee M Glickman |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 38 Years |
| Location | 2 Capital Way Ste 385, Pennington, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295702884 | NPI | - | NPPES |
| 1346962 | Other | NJ | PENNSYLVANIA BLUE SHIELD |
| 5137900 | Medicaid | NJ | |
| 060067986 | Other | NJ | MEDICARE RAILRAOD |
| 0563230000 | Other | NJ | AMERIHEALTH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Health Medical Center - Hopewell | Pennington, NJ | Hospital |
| Capital Health Regional Medical Center | Trenton, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Health Medical Group | 7618264532 | 364 |
News Archive
NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors, a rare pediatric cancer without effective treatments, may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins.
The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.
› Verified 4 days ago
| Entity Name | Capital Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437516887 PECOS PAC ID: 7618264532 Enrollment ID: O20160921000449 |
News Archive
NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors, a rare pediatric cancer without effective treatments, may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins.
The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lee M Glickman, MD 2 Capital Way Ste 385, Pennington, NJ 08534-2521 Ph: (609) 303-4838 | Lee M Glickman, MD 2 Capital Way Ste 385, Pennington, NJ 08534-2521 Ph: (609) 303-4838 |
News Archive
NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors, a rare pediatric cancer without effective treatments, may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins.
The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.
› Verified 4 days ago
Neil Saxena, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Capital Way Ste 385, Pennington, NJ 08534 Phone: 609-303-4838 Fax: 609-303-4835 | |
Madhuri Adabala, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Capital Way, Pennington, NJ 08534 Phone: 609-303-4000 | |
Mowyad Omer Elamin Khalid, M.D Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2 Capital Way Ste 550, Pennington, NJ 08534 Phone: 609-303-4360 Fax: 609-303-4361 | |
Rishi Patel, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Capital Way Ste 550, Pennington, NJ 08534 Phone: 609-303-4360 | |
Dr. Brian Adam Meltzer, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 6 E Acres Dr, Pennington, NJ 08534 Phone: 609-737-1903 Fax: 732-247-5309 | |
Marie Antoinette Marquez, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1300 Merrill Lynch Dr, Pennington, NJ 08534 Phone: 609-274-6000 | |
Anita Maraj, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Capital Way, Pennington, NJ 08534 Phone: 609-303-4000 |